Retatrutide Protocol Calculator
Based on published Phase 2 trial data — Jastreboff et al., NEJM 2023
For informational purposes only. This reflects published clinical trial protocols, not personalized medical advice. Consult a healthcare provider before starting any protocol.
Questions or feedback? support@retapath.com
Select Your Goal
Phase 2 Trial Escalation Protocol
| WEEKS | DOSE | NOTES |
|---|---|---|
| 1-4 | 2mg | Starting dose — all trial arms |
| 5-8 | 4mg | First escalation |
| 9-12 | 8mg | Second escalation |
| 13-16 | 12mg | Third escalation — primary endpoint dose |
| 17-24 | 12mg | Maintenance at 12mg |
Phase 2 Trial Outcomes by Dose
2mg arm · 24 weeks
8.7%
avg body weight lost
4mg arm · 24 weeks
11.6%
avg body weight lost
8mg arm · 24 weeks
14.9%
avg body weight lost
12mg arm · 24 weeks
17.5%
avg body weight lost
Source: Jastreboff AM et al. Retatrutide for obesity. N Engl J Med. 2023;389:514-526. doi:10.1056/NEJMoa2301972
Track your protocol with RetaPath
Log weekly check-ins, monitor biomarkers, and compare your progress against trial benchmarks.
Get Started Free